Key result
The 2021 ACC/AHA/SCAI guidelines can be used to individualize decisions between revascularization and optimal medical therapy to reduce mortality or cardiovascular events in patients with stable ischemic heart disease.
Why the study?
To demonstrate how to apply the 2021 ACC/AHA/SCAI coronary artery revascularization guideline to decide between revascularization and optimal medical therapy in selected patients with stable ischemic heart disease and complex coronary disease.
Case Report (n=3)
This case series illustrates the practical application of the 2021 ACC/AHA/SCAI revascularization guidelines in managing patients with stable ischemic heart disease and complex coronary disease.
This case series shows how the 2021 ACC/AHA/SCAI guideline for coronary artery revascularization can be used to decide between revascularization or optimal medical therapy to reduce mortality or cardiovascular events in selected subsets of patients with stable ischemic heart disease and complex coronary disease with or without left ventricular dysfunction. (Level of Difficulty: Advanced.)
No takes yet. Share an insight, caveat, or question.
Bittl et al. (2021) conducted a case report in Stable ischemic heart disease and complex coronary disease (n=3). Coronary Artery Revascularization (CABG or PCI) vs. Optimal medical therapy was evaluated. The 2021 ACC/AHA/SCAI guidelines can be used to individualize decisions between revascularization and optimal medical therapy to reduce mortality or cardiovascular events in patients with stable ischemic heart disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: